Cardiol Therapeutics (CRDL)
NASDAQ:CRDL
Want to see CRDL full AI Analyst Report?
CRDL Stock Chart & Stats
$1.41
-$0.03(-2.19%)
At close: 4:00 PM EST
$1.41
-$0.03(-2.19%)
Day’s Range― - ―
52-Week Range$0.88 - $1.59
Previous Close$1.33
Volume248.87K
Average Volume (3M)701.45K
Market Cap
$158.94M
Enterprise Value$208.77M
Total Cash (Recent Filing)$21.42M
Total Debt (Recent Filing)$125.52K
Price to Earnings (P/E)―
Beta1.46
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding111,872,086
10 Day Avg. Volume564,759
30 Day Avg. Volume701,452
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.06K
Enterprise Value/Ebitda-6.14
Forecast
1Y Price Target
$8.50Price Target Upside502.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy SignalsPeer-reviewed ARCHER data showing reductions in left ventricular mass and favorable structural trends support the drug's anti-inflammatory effect and strengthen the case for benefit in heart failure programs.
Clinical Trial EnrollmentProgress toward full patient enrollment in the Phase III MAVERIC trial increases the chance of obtaining definitive top-line results that could drive investor interest.
Regulatory PathwayA planned new drug application to the FDA if MAVERIC produces positive results establishes a clear regulatory path that could materially affect company valuation.
Bears Say
Endpoint RobustnessReduced extracellular volume measurements from imaging quality problems materially weakened statistical power for the primary endpoint and may undermine confidence in the trial's conclusions.
Imaging Data QualityImaging limitations reduced the number of analyzable patients in ARCHER, creating gaps in the dataset that complicate interpretation of trial findings.
Statistical PowerA smaller analyzable sample due to imaging issues likely left the primary endpoint underpowered, increasing uncertainty about the formal significance of observed improvements.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was $0.88 and its highest was $1.59 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $158.94M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 31 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Mar 31, 2026. The company reported -$0.051 earnings per share for the quarter, beating the consensus estimate of -$0.066 by $0.015.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 111,872,086 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -$0.051 in its last earnings report, beating expectations of -$0.066. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.50 (502.84% Upside)
$8.50 (502.84% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-46.90%
12-Months-Change
Fundamentals
Return on Equity
-238.02%
Trailing 12-Months
Asset Growth
-22.22%
Trailing 12-Months
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
$8.50
▲(502.84% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Ownership Overview
2.32% Insiders
0.05% Mutual Funds
0.04% Other Institutional Investors
96.81% Public Companies and
Individual Investors